The CBD entourage effect: what studies actually tested
The entourage effect is the hypothesis that hemp's other compounds, minor cannabinoids and terpenes, change the action of CBD or THC. The term dates from 1998 and first described molecules made by the human body. For hemp, neither laboratory tests on cannabinoid receptors nor a controlled trial comparing a full-spectrum oil with a CBD isolate has confirmed it.
Key takeaways
- The 1998 "entourage effect" referred to esters made by the human body that boost an endocannabinoid, 2-AG.
- Ethan Russo extended the idea to hemp's terpenes and cannabinoids in 2011, as a hypothesis.
- In three cell studies from 2019 and 2020, common terpenes neither activated nor modulated the CB1, CB2, TRPV1 and TRPA1 receptors; β-caryophyllene alone showed a possible weak interaction.
- In a 2024 study of 20 adults, limonene lowered self-reported anxiety under THC; CBD was not part of it.
- Epidyolex, the only authorised CBD medicine, contains purified CBD.
1998: a term coined for the human body, not the plant
The term comes from a paper by Raphael Mechoulam's team, with Shimon Ben-Shabat as first author, published in 1998 in the European Journal of Pharmacology. The authors were working on 2-AG, an endocannabinoid: a molecule made by the body that activates cannabinoid receptors. Next to it they found two related esters that do not bind to the receptors but boost the activity of 2-AG, in cell tests and in mice. They named this the "entourage effect".
The first description therefore concerns the endocannabinoid system. Hemp, CBD and terpenes play no part in it, and the move to the plant came later.
2011: Ethan Russo transposes the idea to hemp
The neurologist Ethan Russo published a review titled "Taming THC" in the British Journal of Pharmacology in 2011. Drawing on laboratory data, he proposed that cannabis phytocannabinoids and terpenes act together, each modulating the effect of the others. The paper reviews hypotheses and reports no trial; it lists leads that remain to be tested.
Terpenes are the plant's aromatic molecules: myrcene, limonene, linalool, β-caryophyllene, the pinenes. Our article on hemp terpenes describes their chemistry. Since 2011, Russo's hypothesis has become a common sales argument for oils labelled full spectrum.
What laboratories have tested since
Testing a hypothesis means looking for its traces. If terpenes strengthened cannabinoids, the effect should appear at their targets, the CB1 and CB2 receptors in particular. Four studies looked for it in cells.
| Study | What was tested | Result |
|---|---|---|
| Gertsch et al., PNAS, 2008 | β-caryophyllene on the CB2 receptor | Selective binding and activation of CB2, in cells and in mice |
| Santiago et al., Cannabis and Cannabinoid Research, 2019 | 6 terpenes, alone and with THC, on human CB1 and CB2 | No activation, no change to THC's effect |
| Finlay et al., Frontiers in Pharmacology, 2020 | 5 terpenes with THC, CBD and 2-AG, on CB1 and CB2 | No interaction, except a possible weak one of β-caryophyllene on CB2 |
| Heblinski et al., Cannabis and Cannabinoid Research, 2020 | 7 terpenes on the TRPA1 and TRPV1 channels | No activation, no modulation of cannabinoids |
β-caryophyllene does bind to the CB2 receptor, and it is the only common terpene for which that link is established. The research on it is covered in our article on β-caryophyllene. For the other terpenes, the Australian team concluded in 2019 that if an entourage effect exists, it does not act through the CB1 or CB2 receptors. In 2020 the New Zealand team reached the same finding with another method, receptor binding assays, and a third study found no effect on the TRPA1 and TRPV1 channels.
The hypothesis survives these results, since terpenes might act elsewhere, on absorption for instance or on other targets. What has not been observed is the mechanism brands cite most often: terpenes that "boost" CBD at its receptors.
In humans: one study, and it concerns THC
We found a single controlled human study pairing a terpene with a cannabinoid. It was run at Johns Hopkins University and published in 2024. Twenty healthy adults inhaled, double-blind, vaporised THC alone (15 or 30 mg), limonene alone (1 or 5 mg), both together, or a placebo. Twelve of them came back for a tenth session with 30 mg of THC and 15 mg of limonene.
On its own, limonene produced no change compared with placebo. Added to 30 mg of THC, 15 mg of limonene lowered self-reported anxiety and paranoia scores compared with THC alone. THC's other effects, on cognition, psychomotor performance and vital signs, were unchanged. Two caveats apply. The study is about THC, and CBD was not tested. Ethan Russo is also a co-author, and the university has filed a patent application on the use of limonene.
For CBD, we found no published controlled trial comparing a full-spectrum oil with an isolate at the same dose. The data cited most often come from a 2018 meta-analysis covering 670 patients with treatment-resistant epilepsy, pooled from 11 observational studies. Improvement was reported more often by patients on CBD-rich extracts (71% versus 46% on purified CBD). On the usual clinical criterion, a reduction of at least 50% in seizures, the difference disappears: 37% versus 42%. Two of the three authors were affiliated with companies in the sector, one of them named Entourage Phytolab. The paper itself concludes that the effect still needs confirming in controlled trials.
Epidyolex, the only authorised CBD medicine, is made of purified CBD.
What this changes when choosing an oil
The formats do differ, in their chemistry, and that difference is read on a certificate. A promise of effect tells you nothing about it.
| Format | What it contains | What to check |
|---|---|---|
| Full spectrum | CBD, minor cannabinoids, terpenes, traces of THC | Δ⁹-THC and THCA, under 0.30% |
| Broad spectrum | The same profile, THC removed | That THC is below the limit of quantification |
| Isolate | CBD alone, often at 99% | Purity and the absence of semi-synthetic cannabinoids |
Two facts count for more than the entourage effect. The THC traces in a full-spectrum product can show up in a drug test, even below 0.30%. And in February 2026 EFSA, the European Food Safety Authority, set a provisional safe level of about 2 mg of CBD a day for a 70 kg adult. It concerns supplements with CBD at least 98% pure, so the benchmark applies only to highly purified, isolate-type CBD. Our article on EFSA's reference dose explains it.
Our comparison of full spectrum versus isolate and the definition of broad-spectrum CBD will help you compare formats. Each product page of the CBD oils in the catalogue states its format.
What a brand may say about it in France
According to MILDECA, the French interministerial mission against drugs, products containing CBD may not make therapeutic claims unless they are authorised as medicines, under penalty of criminal sanctions. A brand that presents the entourage effect as a proven benefit is promising a health effect.
| Avoid | Accurate wording |
|---|---|
| "The entourage effect enhances the benefits of CBD" | "The entourage effect is a hypothesis, not confirmed in humans for CBD" |
| "Full spectrum is more effective" | "Full spectrum and isolate have different compositions, readable on the certificate" |
| "Terpenes multiply the action of CBD" | "Terpenes give the product its smell and taste" |
Frequently asked questions
Raphael Mechoulam's team, in a 1998 paper whose first author was Shimon Ben-Shabat. The term described esters made by the human body that boost the endocannabinoid 2-AG. In 2011 Ethan Russo applied the idea to hemp terpenes and cannabinoids.
Not for CBD. In cell tests, common terpenes showed no notable action on the CB1, CB2, TRPV1 or TRPA1 receptors, with the exception of β-caryophyllene on CB2. We found no controlled trial comparing full spectrum and isolate at the same dose.
According to a 2008 study in PNAS, it binds to and activates the CB2 receptor. It is a terpene, also present in black pepper and cloves. That binding tells you nothing about the effect of a CBD oil containing traces of it.
Base the choice on criteria you can check: the CBD content, any traces of THC (which matter if you drive) and the batch certificate. The entourage effect gives you nothing to measure.
At those doses, research does not allow that conclusion. The only controlled human study used vaporised limonene combined with THC in 20 adults, and no CBD oil was involved.
Written by the Phytogrammes team
Each journal article draws on cited primary sources: ANSM, EFSA, EUR-Lex and peer-reviewed publications. Product profiles are distinguished from documented laboratory results. Our approach.
Article published on . CBD is not a medicine.